Written Notification to University. Adaptimmune informing University in writing, pursuant to Article 21 “Notices” of the AAV/HLA-engineering licence, that it wishes to enter into such direct license with University, within the Initial Notice Period;
Appears in 3 contracts
Sources: Research Collaboration and License Agreement (Adaptimmune Therapeutics PLC), Research Collaboration and License Agreement (Adaptimmune Therapeutics PLC), Hla/Aav Sublicence (Adaptimmune Therapeutics PLC)